DaVita (DVA) Stock Movement Summary DaVita's stock rose ahead of its Q4 2025 earnings report scheduled for February 2, 2026 (Monday after market close). Expected Financial Results: - Analysts expect revenue to grow 6.4% year-over-year to $3.51 billion - Adjusted earnings per share expected at $3.19 - The company has generally met revenue expectations in the past - Analyst estimates have remained consistent leading up to this report Factors Cited as Supporting Performance: - Technology upgrades - Cost control measures - Seasonal boosts and seasonal normalization - Operational efficiencies - Favorable revenue adjustments Noted Headwinds: - Ongoing volume headwinds - Elevated mortality rates - Payer mix variability
Read full analysisDaVita (DVA) Stock Movement Summary DaVita's stock rose ahead of its Q4 2025 earnings report scheduled for February 2, 2026 (Monday after market close). Expected Financial Results: - Analysts expect revenue to grow 6.4% year-over-year to $3.51 billion - Adjusted earnings per share expected at $3.19 - The company has generally met revenue expectations in the past - Analyst estimates have remained consistent leading up to this report Factors Cited as Supporting Performance: - Technology upgrades - Cost control measures - Seasonal boosts and seasonal normalization - Operational efficiencies - Favorable revenue adjustments Noted Headwinds: - Ongoing volume headwinds - Elevated mortality rates - Payer mix variability
DaVita Inc. (DVA) is a publicly traded company in the Healthcare sector.